John Lung, MD
Family Medicine · Mission, TXNPI 1952534844
Payments from drug & device makers
Across 276 payments — averaging $641.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$149K
- CSL Behring$28K
- Otsuka America Pharmaceutical, Inc.$114
- Teva Pharmaceuticals USA, Inc.$110
- Alkermes, Inc.$62
- Johnson & Johnson$45
- plus $130 from 6 others
What the payments were for
- Consulting fees$176,550100%
- Food & beverage$4620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 226 | $148,650 |
| CSL Behring | 26 | $27,900 |
| Otsuka America Pharmaceutical, Inc. | 5 | $114 |
| Teva Pharmaceuticals USA, Inc. | 6 | $110 |
| Alkermes, Inc. | 3 | $62 |
| Johnson & Johnson | 2 | $45 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Corium, LLC | 1 | $16 |
| Shire North American Group Inc | 1 | $13 |
| Indivior Inc. | 1 | $13 |
How this compares
$177,012 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 90 | $15,807 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $9,019 |
| JanuviaSitagliptin Phosphate | 11 | $6,443 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 13 | $3,134 |
| Diclofenac Potassium | 48 | $2,015 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 11 | $2,002 |
| Lisinopril | 139 | $1,505 |
| Simvastatin | 134 | $1,440 |
| Gabapentin | 49 | $944 |
| Metformin Hcl | 93 | $942 |
| Glipizide | 59 | $726 |
| Metoprolol Succinate | 24 | $655 |
| Diclofenac Sodium | 17 | $559 |
| Levothyroxine Sodium | 37 | $492 |
| Losartan Potassium | 30 | $398 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Mission
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.